--- title: "Therapeutic Solutions International, Inc. (TSOI.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/TSOI.US.md" symbol: "TSOI.US" name: "Therapeutic Solutions International, Inc." industry: "Pharmaceuticals" --- # Therapeutic Solutions International, Inc. (TSOI.US) | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Location | US Market | | Website | [www.therapeuticsolutionsint.com](https://www.therapeuticsolutionsint.com) | ## Company Profile Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. ... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-19T04:30:14.000Z **Overall: D (0.66)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 174 / 189 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 1.89% | | | Net Profit YoY | 14.48% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 7049.49 | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 85319.00 | | **Multi Score**: D #### Profit Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -189.11% | E | | Profit Margin | -2824.94% | E | | Gross Margin | 77.58% | A | #### Growth Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 1.89% | C | | Net Profit YoY | 14.48% | C | | Total Assets YoY | 3.63% | C | | Net Assets YoY | 28.44% | A | #### Cash Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | -3.54% | D | | OCF YoY | 1.89% | C | #### Operating Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.02 | E | #### Debt Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 53.29% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Therapeutic Solutions International, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "D", "indicators": [ { "name": "ROE", "value": "-189.11%", "rating": "E" }, { "name": "Profit Margin", "value": "-2824.94%", "rating": "E" }, { "name": "Gross Margin", "value": "77.58%", "rating": "A" } ] }, { "name": "Growth", "grade": "C", "indicators": [ { "name": "Revenue YoY", "value": "1.89%", "rating": "C" }, { "name": "Net Profit YoY", "value": "14.48%", "rating": "C" }, { "name": "Total Assets YoY", "value": "3.63%", "rating": "C" }, { "name": "Net Assets YoY", "value": "28.44%", "rating": "A" } ] }, { "name": "Cash", "grade": "C", "indicators": [ { "name": "Cash Flow Margin", "value": "-3.54%", "rating": "D" }, { "name": "OCF YoY", "value": "1.89%", "rating": "C" } ] }, { "name": "Operating", "grade": "E", "indicators": [ { "name": "Turnover", "value": "0.02", "rating": "E" } ] }, { "name": "Security", "grade": "C", "indicators": [ { "name": "Gearing Ratio", "value": "53.29%", "rating": "C" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B | | 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B | | 03 | Roche (US.RHHBY) | A | B | B | D | C | B | | 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B | | 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 0.00 | 59/257 | - | - | - | | PB | 0.01 | 1/257 | 0.84 | 0.56 | 0.01 | | PS (TTM) | 0.08 | 6/257 | 12.19 | 8.11 | 0.08 | | Dividend Yield | 0.00% | - | - | - | - | ## References - [Company Overview](https://longbridge.com/en/quote/TSOI.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/TSOI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/TSOI.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.